Sigyn Therapeutics (SIGY) AI Stock Analysis

• Market Cap: $4.43M
• Dividend Yield: N/A
• Average Volume (3M): 879.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.57
• Revenue Growth: N/A
• EPS Growth: 15.75%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.20
• Shares Outstanding: 1,605,377
• 10 Day Avg. Volume: 460
• 30 Day Avg. Volume: 879
• PEG Ratio: 0.04
• Price to Book (P/B): -0.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 26 Underperform
• Price Target: ―

The overall score reflects significant financial challenges, including persistent net losses, high leverage, and no revenue growth. Technical indicators show mixed signals, with potential short-term upward momentum but risk of being overbought. The valuation is concerning with a negative P/E ratio, suggesting the stock is not a value play. The lack of clear communication in the earnings call adds to the uncertainty. Overall, the stock presents high risk with limited visibility into future improvements.

Sigyn Therapeutics Business Overview & Revenue Model

Company Description

Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.

How the Company Makes Money

Sigyn Therapeutics generates revenue primarily through the commercialization of its blood purification technology, which targets hospitals and healthcare providers treating patients with severe inflammatory conditions. The company may also engage in strategic partnerships or licensing agreements with pharmaceutical companies and medical institutions to expand the application and distribution of its technology. Additionally, Sigyn Therapeutics could potentially receive funding from grants, research collaborations, and government contracts aimed at accelerating the development and deployment of their medical solutions.

Sigyn Therapeutics Financial Statement Overview

Summary

Sigyn Therapeutics is experiencing severe financial difficulties, marked by consistent net losses, high leverage, negative equity, and a lack of revenue growth. These factors indicate significant challenges in achieving profitability and financial stability.

Income Statement

The company has reported consistent net losses over the years, with declining EBIT and EBITDA figures. There is no revenue reported for the latest year, indicating weak revenue generation capabilities. The lack of revenue growth highlights challenges in operational performance and market competitiveness.

Balance Sheet

The balance sheet shows a negative stockholders' equity, indicating insolvency risks. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt level suggests significant leverage, which poses a financial risk. The equity ratio is also negative, reflecting a weak financial structure.

Cash Flow

Operating cash flows are consistently negative, which could indicate poor operational efficiency or high cash burn. Positive financing cash flows suggest reliance on external funding, but free cash flow remains negative, highlighting the company's struggle to generate cash from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.77K	0.00	0.00	0.00	0.00	0.00
Gross Profit	2.89K	0.00	-8.86K	-10.45K	―	-11.30K
EBITDA	-2.26M	-2.52M	-2.45M	-2.14M	-2.53M	-905.13K
Net Income	-3.84M	-3.34M	-4.15M	-3.71M	-3.40M	-1.60M
Balance Sheet
Total Assets	51.76K	213.72K	321.81K	332.88K	710.26K	694.08K
Cash, Cash Equivalents and Short-Term Investments	459.00	12.14K	11.69K	8.36K	340.96K	84.40K
Total Debt	2.57M	2.19M	2.40M	1.88M	933.92K	518.67K
Total Liabilities	5.49M	4.67M	3.73M	2.24M	974.84K	594.90K
Stockholders Equity	-5.44M	-4.46M	-3.41M	-1.90M	-264.58K	99.18K
Cash Flow
Free Cash Flow	-900.92K	-872.44K	-1.38M	-1.83M	-1.80M	-840.61K
Operating Cash Flow	-900.91K	-872.44K	-1.38M	-1.83M	-1.77M	-829.81K
Investing Cash Flow	-4.00	0.00	0.00	-860.00	-29.26K	-10.80K
Financing Cash Flow	847.73K	872.89K	1.39M	1.50M	2.06M	925.01K

Sigyn Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIGY, the sentiment is Negative. The current price of 2.76 is below the 20-day moving average (MA) of 3.59, below the 50-day MA of 3.37, and below the 200-day MA of 3.40, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 33.38 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SIGY.

Sigyn Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PTNT	46 Neutral	$7.64M	―	―	―	-100.00%	64.00%
EVGN	44 Neutral	$10.02M	―	-655.00%	―	-28.72%	43.01%
SLXN	34 Underperform	$8.35M	―	-1342.57%	―	―	-1475.99%
MTVA	33 Underperform	$24.92M	―	-129.46%	―	―	64.35%
RNAZ	27 Underperform	$8.81M	―	-658.62%	―	―	99.45%
SIGY	26 Underperform	$4.43M	―	―	―	―	15.75%